Cotinga Pharmaceuticals Inc (COT):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Cotinga Pharmaceuticals Inc (COT) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C12405
◆発行会社(調査会社):GlobalData
◆発行日:2018年12月
◆ページ数:59
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Cotinga Pharmaceuticals Inc (Cotinga), formerly Critical Outcome Technologies Inc, is a developer of targeted therapeutics with focus on oncology. The company offers pipeline products such as COTI-2 targeting p53 and COTI-259 targeting KRAS. Its research includes program, indication, screening, lead identification, preclinical, among others. Cotinga’s COTI-2 is a novel small molecule activator of misfolded mutant p53 proteins for the treatment of ovarian and other gynecological cancers. It also offers treatment for small cell lung cancer and other products for Alzheimer’s disease, HIV integrase inhibitors, and multiple sclerosis. The company uses its proprietary technology Chemsas, a multistage computational platform technology based on hybrid of machine learning technologies and proprietary algorithms which allows accurate prediction of biological activity from the molecular structure. It serves pharmaceutical and biotechnology companies. Cotinga is headquartered in Boston, Massachusetts, the US.

Cotinga Pharmaceuticals Inc (COT) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Cotinga Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Cotinga Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Cotinga Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Cotinga Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Cotinga Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Cotinga Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 12
Partnerships 12
Critical Outcome Technologies And Portage Biotech To Form Joint Venture 12
Critical Outcome Technologies Enters Into Drug Discovery Agreement With Global Pharma Company 14
Critical Outcome Technologies Enters Into Agreement With Delmar Chemicals To Develop New Drug Candidates 15
Critical Outcome Technologies Enters Into Collaboration Agreement With University of Western Ontario 16
Equity Offering 17
Cotinga Pharma Raises USD1.6 Million in Private Placement of Shares and Warrants 17
Critical Outcome Technologies Raises USD0.4 Million in Second Tranche of Private Placement of Units 18
Critical Outcome Technologies Raises USD1.2 Million in First Tranche of Private Placement of Units 19
Critical Outcome Technologies Raises USD1.2 Million in Private Placement of Shares upon Exercise of Warrants 20
Critical Outcome Technologies Raises USD1 Million in Private Placement of Shares upon Exercise of Warrants 21
Critical Outcome Technologies Raises USD1 Million in Private Placement of Units 22
Critical Outcome Technologies Raises USD1 Million in Private Placement of Shares Upon Exercise of Warrants 23
Critical Outcome Raises USD0.6 Million in Second Tranche of Private Placement of Shares 24
Critical Outcome Raises USD0.36 Million in First Tranche of Private Placement of Shares 25
Critical Outcome Raises USD0.4 Million in Private Placement of Units 26
Critical Outcome Raises USD0.22 Million in Private Placement of Units 27
Critical Outcome Technologies Raises USD0.6 Million in Third Tranche of Private Placement of Units 28
Critical Outcome Technologies Completes Private Placement Of Units For US$0.1 Million 30
Critical Outcome Technologies Completes Third Tranche Of Private Placement Of Units For US$0.12 Million 31
Critical Outcome Technologies Completes Second Tranche of Private Placement of Units for USD0.2 Million 33
Critical Outcome Technologies Completes Private Placement Of Units For US$0.5 Million 34
Critical Outcome Technologies Completes Final Tranche Of Private Placement Of Units For US$0.3 Million 35
Debt Offering 36
Critical Outcome Technologies Completes Private Placement Of Debentures For US$0.4 Million 36
Cotinga Pharmaceuticals Inc – Key Competitors 38
Cotinga Pharmaceuticals Inc – Key Employees 39
Cotinga Pharmaceuticals Inc – Locations And Subsidiaries 40
Head Office 40
Other Locations & Subsidiaries 40
Recent Developments 41
Financial Announcements 41
Oct 02, 2018: Cotinga Pharmaceuticals reports fiscal 2019 first quarter financial and operating results 41
Aug 29, 2018: Cotinga Pharmaceuticals reports fiscal 2018 fourth quarter and full year financial and operating results 43
Apr 03, 2018: Cotinga Pharmaceuticals Reports Fiscal 2018 Third Quarter Financial and Operating Results 45
Dec 29, 2017: Critical Outcome Technologies Reports Fiscal 2018 Second Quarter Financial and Operating Results 47
Sep 29, 2017: Critical Outcome Technologies Reports Fiscal 2018 First Quarter Financial and Operating Results 49
Aug 28, 2017: Critical Outcome Technologies Announces Fourth Quarter and Full Year 2017 Financial Results 51
Mar 16, 2017: Critical Outcome Technologies Reports Third Quarter Financial and Operating Results for Fiscal Year 2017 53
Corporate Communications 54
Jul 02, 2018: Cotinga Pharmaceuticals announces management and board changes 54
May 11, 2017: Critical Outcome Technologies Appoints Experienced Biotech Leader as Chief Scientific Officer 55
Feb 01, 2017: Critical Outcome Technologies Announces Departure of Chief Scientific Officer 56
Other Significant Developments 57
Jan 08, 2018: Critical Outcome Technologies Changes Name to Cotinga Pharmaceuticals 57
Dec 21, 2017: Critical Outcome Technologies Provides Scientific and Business Update at Annual General Meeting and Announces Approval of Name Change 58
Appendix 59
Methodology 59
About GlobalData 59
Contact Us 59
Disclaimer 59

List of Tables
Cotinga Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2018 2
Cotinga Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Cotinga Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Cotinga Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Cotinga Pharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Cotinga Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Critical Outcome Technologies And Portage Biotech To Form Joint Venture 12
Critical Outcome Technologies Enters Into Drug Discovery Agreement With Global Pharma Company 14
Critical Outcome Technologies Enters Into Agreement With Delmar Chemicals To Develop New Drug Candidates 15
Critical Outcome Technologies Enters Into Collaboration Agreement With University of Western Ontario 16
Cotinga Pharma Raises USD1.6 Million in Private Placement of Shares and Warrants 17
Critical Outcome Technologies Raises USD0.4 Million in Second Tranche of Private Placement of Units 18
Critical Outcome Technologies Raises USD1.2 Million in First Tranche of Private Placement of Units 19
Critical Outcome Technologies Raises USD1.2 Million in Private Placement of Shares upon Exercise of Warrants 20
Critical Outcome Technologies Raises USD1 Million in Private Placement of Shares upon Exercise of Warrants 21
Critical Outcome Technologies Raises USD1 Million in Private Placement of Units 22
Critical Outcome Technologies Raises USD1 Million in Private Placement of Shares Upon Exercise of Warrants 23
Critical Outcome Raises USD0.6 Million in Second Tranche of Private Placement of Shares 24
Critical Outcome Raises USD0.36 Million in First Tranche of Private Placement of Shares 25
Critical Outcome Raises USD0.4 Million in Private Placement of Units 26
Critical Outcome Raises USD0.22 Million in Private Placement of Units 27
Critical Outcome Technologies Raises USD0.6 Million in Third Tranche of Private Placement of Units 28
Critical Outcome Technologies Completes Private Placement Of Units For US$0.1 Million 30
Critical Outcome Technologies Completes Third Tranche Of Private Placement Of Units For US$0.12 Million 31
Critical Outcome Technologies Completes Second Tranche of Private Placement of Units for USD0.2 Million 33
Critical Outcome Technologies Completes Private Placement Of Units For US$0.5 Million 34
Critical Outcome Technologies Completes Final Tranche Of Private Placement Of Units For US$0.3 Million 35
Critical Outcome Technologies Completes Private Placement Of Debentures For US$0.4 Million 36
Cotinga Pharmaceuticals Inc, Key Competitors 38
Cotinga Pharmaceuticals Inc, Key Employees 39
Cotinga Pharmaceuticals Inc, Other Locations 40

List of Figures
Cotinga Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Cotinga Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Cotinga Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Cotinga Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Cotinga Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Cotinga Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Cotinga Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Cotinga Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

★海外企業調査レポート[Cotinga Pharmaceuticals Inc (COT):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Banco Comercial Portugues S.A:企業のM&A・事業提携・投資動向
    Banco Comercial Portugues S.A - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Banco Comercial Portugues S.A Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and …
  • Greenhill & Co Inc:企業の戦略・SWOT・財務情報
    Greenhill & Co Inc - Strategy, SWOT and Corporate Finance Report Summary Greenhill & Co Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • NPO Petrovax Pharm LLC:製薬・医療:M&Aディール及び事業提携情報
    Summary NPO Petrovax Pharm LLC (Petrovax) focuses on the research, development and manufacturing of medicines and vaccines. The company’s expertise spans in producing APIs and liquid, semi-solid, and solid dosage forms in ampoules, plastic containers, vials and disposable syringes. It also provides …
  • Petroleos Mexicanos-エネルギー分野:企業M&A・提携分析
    Summary Petroleos Mexicanos (PEMEX) is a state owned vertically integrated oil and gas company. The company explores for, develops and produces crude oil and natural gas. It also refines and markets petroleum products. PEMEX gathers and processes natural gas products. It manufactures and markets a w …
  • EnerVest Ltd:企業のM&A・事業提携・投資動向
    EnerVest Ltd - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's EnerVest Ltd Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, …
  • PhaseRx Inc (PZRX)-医療機器分野:企業M&A・提携分析
    Summary PhaseRx Inc (PhaseRx), formerly PhaseRx Pharmaceuticals Inc is a healthcare products provider that conducts research and develops RNA nanomedicines for the treatment of orphan diseases. The company discovers and develops drugs based on SMARTT polymer technology, which offers mRNA delivery te …
  • Shop Direct Holdings Limited:企業の戦略・SWOT・財務情報
    Shop Direct Holdings Limited - Strategy, SWOT and Corporate Finance Report Summary Shop Direct Holdings Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • Acxiom Corp (ACXM):企業の財務・戦略的SWOT分析
    Acxiom Corp (ACXM) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …
  • Mediq NV:製薬・医療:M&Aディール及び事業提携情報
    Summary Mediq NV (Mediq) is a provider of medical devices, pharmaceuticals and related care services. It offers these services directly to people’s homes (direct), through professional healthcare customers such as hospitals and care institutions (institutional), through wholesalers or through Mediq …
  • Chemo Espana SA-製薬・医療分野:企業M&A・提携分析
    Summary Chemo Espana SA (Chemo Group) is a pharmaceutical company, which conducts research, development, manufacture, sales and marketing of active pharmaceutical ingredients (APIs), finished dosage forms and branded pharmaceuticals. Its product portfolio includes steroids, hormones and antibiotics …
  • Poslovni sistem Mercator, d.d.:企業の戦略・SWOT・財務情報
    Poslovni sistem Mercator, d.d. - Strategy, SWOT and Corporate Finance Report Summary Poslovni sistem Mercator, d.d. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product a …
  • Mitsubishi Gas Chemical Co Inc (4182):企業の財務・戦略的SWOT分析
    Mitsubishi Gas Chemical Co Inc (4182) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths an …
  • Medicago Inc-製薬・医療分野:企業M&A・提携分析
    Summary Medicago Inc (Medicago), a subsidiary of Mitsubishi Tanabe Pharma Corp is a biopharmaceutical company that develops and produces vaccines and antibodies. The company concentrates on the discovery and development of novel vaccines and therapeutic proteins for infectious diseases. Its pipeline …
  • Andritz AG (ANDR):企業の財務・戦略的SWOT分析
    Andritz AG (ANDR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Trident Systems Incorporated:企業の戦略・SWOT・財務情報
    Trident Systems Incorporated - Strategy, SWOT and Corporate Finance Report Summary Trident Systems Incorporated - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • Tek Art Insaat Ticaret Turizm Sanayi Ve Yatirimlar As:企業の戦略・SWOT・財務分析
    Tek Art Insaat Ticaret Turizm Sanayi Ve Yatirimlar As - Strategy, SWOT and Corporate Finance Report Summary Tek Art Insaat Ticaret Turizm Sanayi Ve Yatirimlar As - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's …
  • Sonangol EP:企業のM&A・事業提携・投資動向
    Sonangol EP - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Sonangol EP Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, ca …
  • American Family Insurance Group:企業の戦略・SWOT・財務情報
    American Family Insurance Group - Strategy, SWOT and Corporate Finance Report Summary American Family Insurance Group - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product …
  • PT Tigaraksa Satria Tbk (TGKA):企業の財務・戦略的SWOT分析
    PT Tigaraksa Satria Tbk (TGKA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakn …
  • Altacor Ltd:製薬・医療:M&Aディール及び事業提携情報
    Summary Altacor Ltd (Altacor) is an ophthalmology company that develops and markets orphan products for chronic eye conditions. The company offers prescription and retail ophthalmology products. Its products include dry eye prescription products; dry eye retail products; products for the treatment o …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆